A single-dose oral medication called zoliflodacin shows promise as a new treatment for antibiotic-resistant gonorrhoea, according to a phase 3 clinical trial published in The Lancet. The study found that one dose of zoliflodacin was as effective as the current standard treatment, which combines two antibiotics: an injection of ceftriaxone followed by an oral dose of azithromycin.

About The Study: Consistent with prior work, this study found low adherence (7.3%) to cervical cancer screening guidelines among the commercially insured U.S. population despite stable coverage, likely reflecting guideline confusion among patients, clinicians, and health systems. More evidence-based strategies are needed to expand capacity for guideline-adherent screening, reduce over-screening, and align payer and health system incentives, particularly as new modalities, such as human papillomavirus (HPV) self-sampling, emerge.

Leading microbiologists from Rutgers Health and other institutes say the condition may be driven by company the coronavirus keeps.